Public Employees Retirement Association of Colorado Lowers Position in Globus Medical, Inc. $GMED

Public Employees Retirement Association of Colorado decreased its position in Globus Medical, Inc. (NYSE:GMED) by 14.3% during the 4th quarter, Holdings Channel reports. The fund owned 213,793 shares of the medical device company’s stock after selling 35,600 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Globus Medical were worth $18,666,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in GMED. Advisory Services Network LLC purchased a new stake in shares of Globus Medical in the third quarter valued at about $26,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 197 shares in the last quarter. SBI Securities Co. Ltd. boosted its holdings in shares of Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 167 shares in the last quarter. Parallel Advisors LLC boosted its holdings in shares of Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after acquiring an additional 173 shares in the last quarter. Finally, Headlands Technologies LLC boosted its holdings in shares of Globus Medical by 485.4% in the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after acquiring an additional 631 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Trading Down 3.9%

GMED stock opened at $77.25 on Tuesday. The company has a market cap of $10.49 billion, a P/E ratio of 17.97, a P/E/G ratio of 1.66 and a beta of 0.95. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40. The company’s 50-day moving average price is $85.56 and its 200 day moving average price is $88.00.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The firm had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm’s revenue was up 27.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities research analysts expect that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Royal Bank Of Canada boosted their price objective on shares of Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Piper Sandler decreased their price objective on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a report on Monday. Needham & Company LLC boosted their price objective on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Finally, Wells Fargo & Company decreased their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Globus Medical presently has an average rating of “Moderate Buy” and an average price target of $105.00.

Insider Transactions at Globus Medical

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director owned 510,175 shares in the company, valued at approximately $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 18.38% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.